Globus Medical, Inc. $GMED Shares Sold by SG Americas Securities LLC

Key Points

• SG Americas Securities LLC cut its stake in Globus Medical by 69.5% in Q4, selling 227,879 shares and leaving it with 99,810 shares worth about $8.71 million.
• Company insiders sold a total of 35,594 shares (≈$3.33 million) in the last quarter — including CFO Kyle Kline and EVP Kelly Huller — while insiders still own 18.54% of the stock.
• Despite the selling, Globus Medical beat expectations (Q EPS $1.28 vs. $1.06 est.; revenue $826.4M, up 25.7% YoY) and retains a Moderate Buy consensus with an average target near $104.36.

SG Americas Securities LLC lowered its stake in shares of Globus Medical, Inc. (NYSE:GMED - Free Report) by 69.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 99,810 shares of the medical device company's stock after selling 227,879 shares during the period. SG Americas Securities LLC owned approximately 0.07% of Globus Medical worth $8,714,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Globus Medical by 2.8% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 6,316 shares of the medical device company's stock worth $375,000 after buying an additional 170 shares during the last quarter. Parallel Advisors LLC boosted its holdings in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company's stock valued at $32,000 after acquiring an additional 173 shares during the last quarter. GAMMA Investing LLC grew its position in Globus Medical by 14.7% during the third quarter. GAMMA Investing LLC now owns 1,438 shares of the medical device company's stock valued at $82,000 after acquiring an additional 184 shares during the period. EverSource Wealth Advisors LLC grew its position in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock valued at $27,000 after acquiring an additional 197 shares during the period. Finally, Probity Advisors Inc. increased its stake in Globus Medical by 5.5% during the third quarter. Probity Advisors Inc. now owns 3,792 shares of the medical device company's stock worth $217,000 after acquiring an additional 199 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company's stock.

Insiders Place Their Bets

In other news, CFO Kyle Kline sold 3,594 shares of Globus Medical stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $363,353.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Kelly Huller sold 20,000 shares of the business's stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total value of $1,890,000.00. The SEC filing for this sale provides additional information. Insiders have sold 35,594 shares of company stock worth $3,332,253 in the last quarter. 18.54% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

GMED has been the topic of a number of research reports. Needham & Company LLC raised their price objective on Globus Medical from $112.00 to $114.00 and gave the stock a "buy" rating in a report on Wednesday, February 25th. Citigroup reiterated a "market perform" rating on shares of Globus Medical in a report on Thursday, January 8th. TD Cowen upgraded shares of Globus Medical to a "strong-buy" rating in a report on Tuesday, January 27th. Wells Fargo & Company upgraded shares of Globus Medical to a "strong-buy" rating in a research note on Wednesday, March 18th. Finally, Piper Sandler reissued an "overweight" rating and issued a $115.00 price objective (up from $90.00) on shares of Globus Medical in a research report on Thursday, January 8th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $104.36.

Globus Medical Stock Performance

Globus Medical stock opened at $83.51 on Tuesday. The stock's 50 day moving average price is $89.28 and its 200 day moving average price is $80.52. The firm has a market capitalization of $11.29 billion, a PE ratio of 21.19, a price-to-earnings-growth ratio of 1.96 and a beta of 1.05. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40.

Globus Medical (NYSE:GMED - Get Free Report) last issued its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.22. The company had revenue of $826.42 million during the quarter, compared to the consensus estimate of $803.29 million. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. Globus Medical's revenue for the quarter was up 25.7% on a year-over-year basis. During the same quarter last year, the company earned $0.84 earnings per share. On average, analysts forecast that Globus Medical, Inc. will post 3.44 earnings per share for the current fiscal year.

About Globus Medical

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.